GO:0047939 L-glucuronate reductase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0047939 (L-glucuronate reductase activity) catalyzes the NADPH-dependent reduction of D-glucuronate to L-gulonate, a reversible step in the glucuronic acid pathway.
• The enzyme is also known as L-hexonate dehydrogenase, aldehyde reductase II, or glucuronate reductase, and belongs to the aldo-keto reductase superfamily.
• It is widely distributed in mammalian tissues, with high activity in liver, kidney, and brain, where it participates in ascorbic acid synthesis and glucuronate interconversion.
• The enzyme is inhibited by aldose reductase inhibitors such as sorbinil, statil, and valproate, linking it to polyol pathway research.
• Genetic studies in mice identified the Ahr-1 locus, which encodes aldehyde reductase and is linked to the alcohol dehydrogenase gene complex on chromosome 3.
• Studying GO:0047939 requires combining enzyme assays, CRISPR knockout/knock-in models, and metabolomics to dissect its role in metabolic and neurological disorders.
Description
L-glucuronate reductase activity (GO:0047939) is a molecular function that catalyzes the reversible NADPH-dependent conversion of D-glucuronate to L-gulonate. This reaction is a key step in the glucuronic acid pathway, which interconverts sugar acids and contributes to ascorbic acid biosynthesis in mammals capable of producing vitamin C. The enzyme is also referred to as L-hexonate dehydrogenase or aldehyde reductase II, reflecting its broad substrate specificity within the aldo-keto reductase family. Researchers study this activity because it links carbohydrate metabolism, detoxification, and redox balance, and because its dysregulation has been implicated in diabetic complications and neurological conditions. Understanding GO:0047939 at the molecular level provides a foundation for targeting it in metabolic and inflammatory diseases.
L-glucuronate reductase activity At A Glance
| GO ID | GO:0047939 |
|---|---|
| GO term | L-glucuronate reductase activity |
| Ontology | molecular_function |
| Synonym | Aldehyde reductase II activity; D-glucuronate dehydrogenase activity; D-glucuronate reductase activity; glucuronate dehydrogenase activity; glucuronate reductase activity; NADP-L-gulonate dehydrogenase activity; TPN-L-gulonate dehydrogenase activity |
| Definition | Catalysis of the reaction: L-gulonate + NADP+ = D-glucuronate + H+ + NADPH. |
| Major function | NADPH-dependent reduction of D-glucuronate to L-gulonate, a reversible step in the glucuronic acid pathway. |
| Cofactor | NADP+/NADPH |
| Subcellular location | Cytosol (soluble enzyme) |
| Tissue distribution | Liver, kidney, brain, and other mammalian tissues |
What Is GO:0047939?
GO:0047939 describes the catalytic activity that converts L-gulonate and NADP+ into D-glucuronate, a proton, and NADPH, and vice versa. In other words, it is an oxidoreductase that transfers electrons between NADP+/NADPH and the sugar acid substrates D-glucuronate and L-gulonate. The reaction is reversible and is part of the glucuronic acid cycle, which also involves other enzymes such as glucuronokinase and L-gulonate dehydrogenase.
Why Is L-glucuronate reductase activity Important in Cell Biology?
GO:0047939 is important because it sits at the intersection of carbohydrate metabolism, redox homeostasis, and detoxification. The enzyme interconverts D-glucuronate and L-gulonate, thereby influencing the availability of glucuronic acid for glycosaminoglycan synthesis and xenobiotic conjugation. Its activity is also linked to the polyol pathway, where it may contribute to osmotic and oxidative stress in diabetic tissues. In the brain, L-hexonate dehydrogenase helps maintain the balance of sugar acids and may protect against carbonyl stress. Genetic variation in the enzyme, as shown by the mouse Ahr-1 locus, affects aldehyde reductase activity and alcohol-related traits. Thus, understanding GO:0047939 is relevant to metabolic disorders, neuroprotection, and drug development.
• Participates in the glucuronic acid pathway, which supplies glucuronic acid for glycosaminoglycans and detoxification.
• Contributes to ascorbic acid biosynthesis in mammals that can synthesize vitamin C.
• May modulate polyol pathway flux and osmotic stress in diabetic complications.
• Expressed in brain, suggesting a role in neuronal redox balance and carbonyl detoxification.
• Inhibited by aldose reductase inhibitors, making it a potential off-target in drug development.
• Genetic polymorphisms in the mouse Ahr-1 locus affect aldehyde reductase activity and ethanol response.
• Provides a model for studying aldo-keto reductase evolution and substrate specificity.
• Relevant to metabolic engineering of vitamin C production in microorganisms.
• Potential biomarker for liver and kidney function due to tissue distribution.
• Target for understanding hydrazine toxicity and ascorbic acid metabolism.
What Happens During L-glucuronate reductase activity?
Substrate binding and cofactor recruitment
In simple terms: The enzyme grabs D-glucuronate and a helper molecule called NADPH.
The active site of L-glucuronate reductase binds D-glucuronate and the cofactor NADPH. The enzyme belongs to the aldo-keto reductase superfamily, which typically uses a TIM-barrel fold to coordinate the nicotinamide ring and the sugar acid substrate. Binding is reversible, allowing the enzyme to also catalyze the reverse reaction with L-gulonate and NADP+.
Hydride transfer and reduction
In simple terms: A hydrogen atom is moved from NADPH to the sugar, turning D-glucuronate into L-gulonate.
The catalytic mechanism involves a hydride transfer from the C4 position of the nicotinamide ring of NADPH to the C1 aldehyde group of D-glucuronate, forming L-gulonate. This step is stereospecific and requires a proton donor, often a tyrosine or lysine residue in the active site. The reaction is reversible, and the equilibrium can favor either direction depending on substrate and cofactor concentrations.
Product release and cofactor recycling
In simple terms: The new product L-gulonate is released, and NADP+ is recycled back to NADPH.
After reduction, L-gulonate leaves the active site, and NADP+ is released. The NADP+ can be reduced back to NADPH by other enzymes such as glucose-6-phosphate dehydrogenase or malic enzyme, maintaining the redox balance required for continued activity. This recycling is essential for the enzyme's role in the glucuronic acid pathway.
Integration with the glucuronic acid pathway
In simple terms: The reaction is one step in a larger chain that converts sugars and makes vitamin C.
L-glucuronate reductase activity is part of the glucuronic acid pathway, which interconverts D-glucuronate, L-gulonate, and other sugar acids. In mammals, L-gulonate can be further metabolized to ascorbic acid in species that retain the enzyme L-gulono-1,4-lactone oxidase. The pathway also supplies glucuronic acid for conjugation reactions and glycosaminoglycan synthesis.
Key Genes Involved in GO:0047939 L-glucuronate reductase activity
The following genes and proteins are experimentally linked to L-glucuronate reductase activity or its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AKR1A1 | Aldehyde reductase, may exhibit L-hexonate dehydrogenase activity | Model for substrate specificity and inhibitor design |
| AKR1B1 | Aldose reductase, related aldo-keto reductase | Comparison of polyol pathway enzymes |
| Ahr-1 | Mouse locus encoding aldehyde reductase | Genetic linkage to alcohol dehydrogenase complex |
| GULO | L-gulono-1,4-lactone oxidase, downstream of L-gulonate | Ascorbic acid synthesis in mammals |
| UGDH | UDP-glucose dehydrogenase, upstream of glucuronate | Glucuronic acid supply |
| GLCAK | Glucuronokinase, phosphorylates D-glucuronate | Glucuronic acid pathway |
| NADP | Cofactor for the reductase reaction | Redox balance |
| SORD | Sorbitol dehydrogenase, polyol pathway | Metabolic overlap |
| TKT | Transketolase, links to pentose phosphate pathway | NADPH supply |
| G6PD | Glucose-6-phosphate dehydrogenase, generates NADPH | Cofactor recycling |
| ME1 | Malic enzyme, generates NADPH | Cofactor recycling |
| ALDH2 | Aldehyde dehydrogenase, related detoxification | Aldehyde metabolism |
| ADH1 | Alcohol dehydrogenase, linked to Ahr-1 | Ethanol metabolism |
| SLC2A1 | GLUT1, glucose transport | Substrate availability |
| SLC5A1 | SGLT1, glucose transport | Substrate availability |
| HNF4A | Liver-enriched transcription factor | Regulation of metabolic genes |
| NRF2 | Oxidative stress response | Regulation of antioxidant genes |
How Is L-glucuronate reductase activity Regulated?
L-glucuronate reductase activity is regulated at multiple levels. Enzyme abundance varies by tissue, with high levels in liver and kidney, suggesting transcriptional control by metabolic and hormonal signals. The activity is also modulated by substrate availability and NADPH/NADP+ ratio, which is influenced by the pentose phosphate pathway and malic enzyme. Inhibitors such as sorbinil, statil, and valproate can directly block the enzyme, indicating pharmacological regulation. In mouse genetics, the Ahr-1 locus affects aldehyde reductase activity, and its linkage to the alcohol dehydrogenase complex suggests genetic regulation. Additionally, hydrazine treatment alters ascorbic acid-metabolizing enzymes, including L-hexonate dehydrogenase, in rats.
L-glucuronate reductase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AKR1A1 | Diabetic complications, oxidative stress | CRISPR knockout in retinal cells |
| AKR1B1 | Diabetic retinopathy, neuropathy | Knock-in of human variant in mouse |
| Ahr-1 | Alcohol sensitivity, metabolic traits | Mouse knockout of Ahr-1 locus |
| GULO | Vitamin C deficiency (scurvy) | Gulo-/- mouse model |
| UGDH | Connective tissue disorders | CRISPR point mutation in UGDH |
Diabetic complications
L-glucuronate reductase activity is part of the polyol pathway, which is activated in diabetes. Aldose reductase inhibitors that target this pathway also inhibit L-hexonate dehydrogenase, suggesting that the enzyme may contribute to osmotic and oxidative stress in diabetic tissues such as retina and nerve. However, the exact role of GO:0047939 in diabetic pathology remains to be fully defined.
Neurological disorders
The enzyme is present in human brain, where it may protect against carbonyl stress and maintain redox balance. Alterations in aldehyde reductase activity have been linked to neurodegenerative conditions, although direct evidence for L-glucuronate reductase in these diseases is limited. The mouse Ahr-1 locus, which encodes a related aldehyde reductase, influences ethanol sensitivity and may model aspects of alcohol-related neurobiology.
Metabolic and liver disorders
High expression in liver and kidney suggests a role in systemic metabolism. The enzyme interconverts glucuronate and gulonate, affecting glucuronic acid availability for detoxification and glycosaminoglycan synthesis. Hydrazine exposure alters ascorbic acid metabolism, implicating the enzyme in toxicological responses.
From L-glucuronate reductase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of L-glucuronate reductase affect glucuronic acid pathway flux? | CRISPR knockout of AKR1A1 in HepG2 cells |
| What is the effect of a catalytic point mutation on enzyme activity? | CRISPR point mutation (e.g., Y48F) in AKR1A1 |
| Can a disease-associated variant alter substrate specificity? | Knock-in of human SNP in mouse Ahr-1 locus |
| Where is the enzyme localized in cells? | Tagged knock-in with GFP in HEK293T |
| Does overexpression protect against oxidative stress? | Overexpression of AKR1A1 in neuronal cells |
| What is the metabolic impact of enzyme inhibition? | CRISPR knockout combined with metabolomics in liver organoids |
How to Study the L-glucuronate reductase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| NADPH oxidation assay | Enzyme activity | Kinetic characterization |
| CRISPR knockout | Loss-of-function phenotype | Metabolic flux analysis |
| CRISPR point mutation | Catalytic residue function | Mechanistic studies |
| Knock-in tagging | Subcellular localization | Live-cell imaging |
| Metabolomics (LC-MS) | Substrate/product levels | Pathway flux |
| RNA-seq | Transcriptional changes | Regulatory network |
| Western blot | Protein expression | Tissue distribution |
| Inhibitor profiling | Drug sensitivity | Pharmacological targeting |
Enzyme activity assays
L-glucuronate reductase activity can be measured spectrophotometrically by monitoring NADPH oxidation at 340 nm or NADP+ reduction. Substrate specificity and kinetic parameters (Km, Vmax) are determined using purified enzyme or cell lysates. Inhibitor studies with sorbinil or valproate can assess pharmacological sensitivity.
CRISPR-based genetic models
CRISPR/Cas9 knockout, point mutation, and knock-in models allow causal testing of the enzyme's role. For example, knockout of AKR1A1 in cell lines can reveal metabolic consequences, while knock-in of the mouse Ahr-1 locus can model genetic variation. These models are combined with metabolomics to trace flux through the glucuronic acid pathway.
Metabolomics and flux analysis
Mass spectrometry-based metabolomics quantifies D-glucuronate, L-gulonate, and related metabolites in cells and tissues. Isotope tracing with 13C-labeled glucose can measure flux through the pathway and assess the contribution of L-glucuronate reductase. This approach is essential for linking enzyme activity to metabolic phenotypes.
Expression and localization studies
Quantitative PCR, Western blotting, and immunofluorescence are used to determine tissue distribution and subcellular localization. The enzyme is cytosolic, but tagged knock-in models can confirm localization in live cells. These methods help validate CRISPR models and assess off-target effects.
How CRISPR Can Be Used to Study GO:0047939 L-glucuronate reductase activity
Knockout
CRISPR knockout of genes encoding L-glucuronate reductase activity, such as AKR1A1, can abolish enzyme activity and reveal its contribution to glucuronic acid metabolism. Knockout cell lines are used to measure changes in L-gulonate and D-glucuronate levels, and to test compensatory pathways. In vivo knockout models can assess systemic effects on ascorbic acid synthesis and detoxification.
Point Mutation
Point mutations in catalytic residues (e.g., tyrosine or lysine in the active site) can be introduced by CRISPR to dissect the mechanism. Such mutants help confirm the role of specific amino acids in hydride transfer and substrate binding. They also provide tools to study disease-associated variants without confounding effects of complete loss of protein.
Knock-in
Knock-in of epitope tags (e.g., FLAG, GFP) allows visualization and purification of the enzyme. Knock-in of human disease variants into mouse models can test their functional impact in vivo. This approach is valuable for studying the Ahr-1 locus and its link to alcohol metabolism.
Overexpression
Overexpression of L-glucuronate reductase in cell lines can increase flux through the glucuronic acid pathway and protect against oxidative stress. It is used to study gain-of-function effects and to produce recombinant enzyme for structural studies. Overexpression models also help identify downstream metabolic changes.
How EDITGENE Supports L-glucuronate reductase activity Research
Researchers studying L-glucuronate reductase activity-related genes often need to determine whether a candidate gene is causally involved in metabolic flux, redox balance, or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell models, enabling rigorous functional validation.
Contact EDITGENE today to design your custom CRISPR model for L-glucuronate reductase activity research.
Frequently Asked Questions About L-glucuronate reductase activity
What is L-glucuronate reductase activity?
L-glucuronate reductase activity (GO:0047939) is a molecular function that catalyzes the NADPH-dependent conversion of D-glucuronate to L-gulonate, a reversible step in the glucuronic acid pathway.
What genes are involved in L-glucuronate reductase activity?
Genes such as AKR1A1, AKR1B1, and the mouse Ahr-1 locus encode enzymes with this activity or related aldehyde reductase functions.
What is the reaction catalyzed by GO:0047939?
The reaction is: L-gulonate + NADP+ = D-glucuronate + H+ + NADPH, as defined by QuickGO.
Where is L-glucuronate reductase expressed?
The enzyme is found in liver, kidney, brain, and other mammalian tissues, with high activity in liver and kidney.
What diseases are linked to L-glucuronate reductase activity?
It has been implicated in diabetic complications, neurological disorders, and metabolic liver conditions, though direct evidence is still emerging.
How can I study L-glucuronate reductase activity?
Enzyme assays, CRISPR knockout/knock-in models, metabolomics, and inhibitor profiling are common approaches.
What are the inhibitors of L-glucuronate reductase?
Aldose reductase inhibitors such as sorbinil, statil, M79175, and valproate inhibit L-hexonate dehydrogenase activity.
Is L-glucuronate reductase the same as aldose reductase?
No, they are distinct enzymes but share overlapping substrate specificity and inhibitor sensitivity within the aldo-keto reductase family.
What is the role of L-glucuronate reductase in ascorbic acid synthesis?
It converts D-glucuronate to L-gulonate, a precursor in the ascorbic acid pathway in mammals capable of vitamin C synthesis.
How does the mouse Ahr-1 locus relate to L-glucuronate reductase?
Ahr-1 encodes aldehyde reductase, which has L-hexonate dehydrogenase activity, and is linked to the alcohol dehydrogenase gene complex on chromosome 3.
Conclusion
L-glucuronate reductase activity (GO:0047939) is a key enzymatic function in the glucuronic acid pathway, with roles in ascorbic acid synthesis, redox balance, and detoxification. Its broad tissue distribution and inhibition by aldose reductase inhibitors highlight its relevance to metabolic and neurological diseases. Continued research using CRISPR models and metabolomics will clarify its precise physiological and pathological functions.
References
- 1. Griffin BW. 1992. Functional and structural relationships among aldose reductase, L-hexonate dehydrogenase (aldehyde reductase), and recently identified homologous proteins.. Enzyme Microb Technol 14(9):690-5 PMID: 1368891
- 2. DuPriest MT et al.. 1991. Spiro[fluoreneisothiazolidin]one dioxides: new aldose reductase and L-hexonate dehydrogenase inhibitors.. J Med Chem 34(11):3229-34 PMID: 1956041
- 3. Markus HB et al.. 1983. Tissue distribution of mammalian aldose reductase and related enzymes.. Biochem Med 29(1):31-45 PMID: 6404249
- 4. Chatterjee AK et al.. 1982. Studies on the possible mechanism of hydrazine action on ascorbic acid-metabolising enzymes.. Int J Vitam Nutr Res 52(2):169-75 PMID: 7129798
- 5. STIRPE F et al.. 1965. REGULATION OF ASCORBIC ACID AND OF XYLULOSE SYNTHESIS IN RAT-LIVER EXTRACTS. THE EFFECT OF STARVATION ON THE ENZYMES OF THE GLUCURONIC ACID PATHWAY.. Biochem J 95(2):354-62 PMID: 14340084
- 6. Poulsom R. 1986. Inhibition of hexonate dehydrogenase and aldose reductase from bovine retina by sorbinil, statil, M79175 and valproate.. Biochem Pharmacol 35(17):2955-9 PMID: 3091036
- 7. O'Brien MM et al.. 1980. Polyol-pathway enzymes of human brain. Partial purification and properties of aldose reductase and hexonate dehydrogenase.. Biochem J 187(1):21-30 PMID: 6773519
- 8. Duley JA et al.. 1982. Biochemical genetics of aldehyde reductase in the mouse: Ahr-1--a new locus linked to the alcohol dehydrogenase gene complex on chromosome 3.. Biochem Genet 20(11-12):1067-83 PMID: 6762206
